Vimarsana
Biggest News Aggregation in the World

Patrickj Gallagher News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrickj Gallagher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrickj Gallagher Today - Breaking & Trending Today

Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center ("VIC") at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases -October 05, 2023 at 08:32 am EDT - Vimarsana News

Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center ("VIC") at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases -October 05, 2023 at 08:32 am EDT

Published: October 5, 2023

JUPITER, Fla., Oct. 05, 2023 -- Dyadic International, Inc. , a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Source: marketscreener.com
Related Topics:
United StatesMark EmalfarbMark PoznanskyPatrickj GallagherVoltron Therapeutics IncUs Department Of Defense DoImmunotherapy Center At MassachusettsSecurities ExchangeDyadic International IncImmunotherapy CenterDyadic InternationalMassachusetts General HospitalVoltron TherapeuticsSelf Assembling VaccineChief ExecutiveMassachusetts GeneralEmerging InfectiousLassa FeverSecurities ActSecurities Exchange Act
Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center ("VIC") at Massachusetts ... | Region - Vimarsana News

Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center ("VIC") at Massachusetts ... | Region

Published: October 5, 2023

JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms

Source: eagletribune.com
Related Topics:
United StatesPatrickj GallagherMark EmalfarbMark PoznanskyVoltron Therapeutics IncImmunotherapy Center At MassachusettsUs Department Of Defense DoSecurities ExchangeImmunotherapy CenterDyadic InternationalDyadic International IncMassachusetts General HospitalVoltron TherapeuticsSelf Assembling VaccineChief ExecutiveMassachusetts GeneralEmerging InfectiousLassa FeverSecurities ActSecurities Exchange Act
BioSig Technologies : Annual report pursuant to Section 13 and 15(d) - Vimarsana News

BioSig Technologies : Annual report pursuant to Section 13 and 15(d)

Published: March 31, 2023

Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases , which amended... | March 31, 2023

Source: marketscreener.com
Related Topics:
University Of TexasUnited StatesState Of DelawareUniversity Of MinnesotaWhite HouseDistrict Of ColumbiaNew YorkSanta Barbara Cottage HospitalUniversity Of MassachusettsSouth CarolinaSan AntonioNew JerseyMayo Clinic In RochesterUnited KingdomNew York UniversityEteläuomen LäiNew VernonUnion CollegeFrance GeneralMethodist HospitalGreat BritainJohn SieckhausPatrickj GallagherJamesj BarryAndrew Brenyo
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study - Vimarsana News

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study

Published: July 14, 2022

/PRNewswire/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that data from the previously announce Study '098 demonstrated...

Source: prnewswire.com
Related Topics:
United StatesMatthew DuffyMark PoznanskyJames AhernPatrickj GallagherPatrick GallagherExchange CommissionPrnewswire Voltron Therapeutics IncVoltron Therapeutics IncImmunotherapy CenterLucius PartnersLaidlaw Company United KingdomMassachusetts General HospitalOverall SurvivalProof Of ConceptSelf Assembling VaccinePrimary EndpointChief Executive OfficerManaging PartnerUnited KingdomVoltron TherapeuticsEmerging InfectiousLassa FeverPrivate Securities Litigation Reform ActVaxcelerate Platform